[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2019004549A - Combinaciones que comprenden un inhibidor ssao/vap-1 y un inhibidor sglt2 y usos de los mismos. - Google Patents

Combinaciones que comprenden un inhibidor ssao/vap-1 y un inhibidor sglt2 y usos de los mismos.

Info

Publication number
MX2019004549A
MX2019004549A MX2019004549A MX2019004549A MX2019004549A MX 2019004549 A MX2019004549 A MX 2019004549A MX 2019004549 A MX2019004549 A MX 2019004549A MX 2019004549 A MX2019004549 A MX 2019004549A MX 2019004549 A MX2019004549 A MX 2019004549A
Authority
MX
Mexico
Prior art keywords
inhibitor
ssao
vap
disorders
combinations
Prior art date
Application number
MX2019004549A
Other languages
English (en)
Inventor
Mark Michael
Klein Thomas
Williams Mayoux Eric
Rippmann Joerg
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MX2019004549A publication Critical patent/MX2019004549A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invención se refiere a una combinación farmacéutica de conformidad con la invención que comprende un inhibidor de SSAO/VAP-1 de conformidad con la fórmula (I) (ver fórmula I) en donde R1 a R6, y X son de conformidad con lo definido en la presente, y un inhibidor de SGLT2. Además, la presente invención se refiere a métodos para prevenir, retardar la progresión de, retrasar o tratar trastornos fibróticos, trastornos metabólicos, trastornos inflamatorios, enfermedades oculares, trastornos neuroinflamatorios o cáncer en un paciente necesitado del tratamiento, caracterizado porque la combinación farmacéutica de conformidad con la invención se administra al paciente.
MX2019004549A 2016-10-19 2017-10-16 Combinaciones que comprenden un inhibidor ssao/vap-1 y un inhibidor sglt2 y usos de los mismos. MX2019004549A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16194572 2016-10-19
PCT/EP2017/076300 WO2018073154A1 (en) 2016-10-19 2017-10-16 Combinations comprising an ssao/vap-1 inhibitor and a sglt2 inhibitor, uses thereof

Publications (1)

Publication Number Publication Date
MX2019004549A true MX2019004549A (es) 2019-06-12

Family

ID=57178303

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019004549A MX2019004549A (es) 2016-10-19 2017-10-16 Combinaciones que comprenden un inhibidor ssao/vap-1 y un inhibidor sglt2 y usos de los mismos.

Country Status (14)

Country Link
US (1) US20210212968A1 (es)
EP (1) EP3528800A1 (es)
JP (1) JP2019531320A (es)
KR (1) KR20190070956A (es)
CN (1) CN109843279A (es)
AU (1) AU2017344882A1 (es)
BR (1) BR112019005930A2 (es)
CA (1) CA3041169A1 (es)
CL (1) CL2019000935A1 (es)
EA (1) EA201990951A1 (es)
IL (1) IL265989A (es)
MX (1) MX2019004549A (es)
PH (1) PH12019500845A1 (es)
WO (1) WO2018073154A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190110736A (ko) 2018-03-21 2019-10-01 주식회사유한양행 신규의 트라이아졸론 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
KR20190110740A (ko) 2018-03-21 2019-10-01 주식회사유한양행 신규의 아릴 또는 헤테로아릴 트라이아졸론 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
US12037334B2 (en) 2018-09-28 2024-07-16 Acucela Inc. Inhibitors of VAP-1
CA3114208A1 (en) 2018-09-28 2020-04-02 Acucela Inc. Inhibitors of vap-1
JP7414230B2 (ja) * 2018-11-09 2024-01-16 国立大学法人 琉球大学 抗血液悪性腫瘍薬
TWI835945B (zh) * 2018-12-14 2024-03-21 南韓商柳韓洋行股份有限公司 3,3-二氟烯丙胺化物或其鹽及包含彼的醫藥組合物
TW202039486A (zh) * 2018-12-14 2020-11-01 南韓商柳韓洋行股份有限公司 三唑并吡啶-3-酮化物或其鹽及包含彼之醫藥組合物
US11472769B2 (en) 2019-10-29 2022-10-18 Eccogene (Shanghai) Co., Ltd. SSAO inhibitors and use thereof
PE20230997A1 (es) * 2020-03-25 2023-06-26 Terns Inc Tratamiento de trastornos respiratorios
WO2021231644A1 (en) * 2020-05-13 2021-11-18 Terns Pharmaceuticals, Inc. Combination treatment of liver disorders
CN113893256A (zh) * 2020-07-06 2022-01-07 诺未科技（北京）有限公司 化合物或其可药用盐、二聚体或三聚体在制备治疗癌症的药物中的应用
CN116615416A (zh) 2020-08-25 2023-08-18 伊莱利利公司 Ssao抑制剂的多晶型物
US20240148767A1 (en) * 2021-03-04 2024-05-09 The Governors Of The University Of Alberta The use of empagliflozin for the treatment of ulcerative colitis and crohn's disease
AU2022384271A1 (en) * 2021-11-11 2024-06-20 Terns Pharmaceuticals, Inc. Treating liver disorders with an ssao inhibitor
CA3238082A1 (en) * 2021-11-11 2023-05-19 Terns Pharmaceuticals, Inc. Combination of a ssao inhibitor and thr-beta agonist for use in the treatment of liver disorders

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100591585B1 (ko) 1999-08-31 2006-06-20 깃세이 야쿠힌 고교 가부시키가이샤 글루코피라노실옥시피라졸 유도체, 그것을 함유하는 의약조성물 및 그 제조 중간체
US6515117B2 (en) 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
PH12000002657B1 (en) 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
WO2002044192A1 (fr) 2000-11-30 2002-06-06 Kissei Pharmaceutical Co., Ltd. Derives de glucopyranosyloxybenzylbenzene, compositions medicinales contenant ces derives et produits intermediaires obtenus lors de l'elaboration de ces compositions
CA2432145C (en) 2000-12-28 2010-07-13 Kissei Pharmaceutical Co., Ltd. Glucopyranosyloxypyrazole derivatives and use thereof in medicines
KR100945455B1 (ko) 2002-03-22 2010-03-05 깃세이 야쿠힌 고교 가부시키가이샤 글루코피라노실옥시벤질 벤젠 유도체의 결정
DE10231370B4 (de) 2002-07-11 2006-04-06 Sanofi-Aventis Deutschland Gmbh Thiophenglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
CN1802366B (zh) 2003-03-14 2010-12-22 安斯泰来制药有限公司 C-糖苷衍生物及其盐
EA010299B1 (ru) 2003-08-01 2008-08-29 Мицубиси Танабе Фарма Корпорейшн Новые соединения, обладающие ингибирующей активностью в отношении натрийзависимого транспортёра
SI1730131T1 (sl) 2004-03-16 2012-08-31 Boehringer Ingelheim Int Glukopiranozil-substituirani benzenski derivati, zdravila, ki vsebujejo te spojine, njihova uporaba in postopek za njihovo pripravo
TW200637839A (en) 2005-01-07 2006-11-01 Taisho Pharmaceutical Co Ltd 1-thio-d-glucitol derivatives
TW200637869A (en) 2005-01-28 2006-11-01 Chugai Pharmaceutical Co Ltd The spiroketal derivatives and the use as therapeutical agent for diabetes of the same
UA91546C2 (uk) 2005-05-03 2010-08-10 Бьорінгер Інгельхайм Інтернаціональ Гмбх КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ
US7772191B2 (en) 2005-05-10 2010-08-10 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
JP2009531291A (ja) 2006-02-15 2009-09-03 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング グルコピラノシル置換ベンゾニトリル誘導体、それらの化合物を含有する医薬組成物、それらの使用及び製造方法
WO2007140191A2 (en) 2006-05-23 2007-12-06 Theracos, Inc. Glucose transport inhibitors and methods of use
US7919598B2 (en) 2006-06-28 2011-04-05 Bristol-Myers Squibb Company Crystal structures of SGLT2 inhibitors and processes for preparing same
TWI499414B (zh) 2006-09-29 2015-09-11 Lexicon Pharmaceuticals Inc 鈉與葡萄糖第２型共同運輸體（ｃｏ-ｔｒａｎｓｐｏｒｔｅｒ ２）的抑制物與其應用方法
UY30730A1 (es) 2006-12-04 2008-07-03 Mitsubishi Tanabe Pharma Corp Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno
US7846945B2 (en) 2007-03-08 2010-12-07 Lexicon Pharmaceuticals, Inc. Piperdine-based inhibitors of sodium glucose co-transporter 2 and methods of their use
PE20090185A1 (es) 2007-03-22 2009-02-28 Bristol Myers Squibb Co Formulaciones farmaceuticas que contienen un inhibidor sglt2
CA2694029C (en) 2007-07-26 2016-10-04 Lexicon Pharmaceuticals, Inc. Methods and compounds useful for the preparation of sodium glucose co-transporter 2 inhibitors
CA2699285C (en) 2007-09-10 2016-12-13 Ahmed F. Abdel-Magid Process for the preparation of compounds useful as inhibitors of sodium-dependent glucose transporter (sglt)
WO2009066152A2 (en) 2007-11-21 2009-05-28 Pharmaxis Ltd. Haloallylamine inhibitors of ssao/vap-1 and uses therefor
TW201011043A (en) 2008-06-20 2010-03-16 Chugai Pharmaceutical Co Ltd Crystal of spiroketal derivatives and process for preparation of spiroketal derivatives
TWI472521B (zh) 2008-07-17 2015-02-11 Lexicon Pharmaceuticals Inc （２ｓ，３ｒ，４ｒ，５ｓ，６ｒ）－２－（４－氯－３－（４－乙氧苄基）苯基）－６－（甲硫）四氫－２ｈ－哌喃－３，４，５－三醇的固體形態與其使用方法
JP4825322B1 (ja) 2008-08-28 2011-11-30 ファイザー・インク ジオキサ−ビシクロ［３．２．１］オクタン−２，３，４−トリオール誘導体
FI2395968T3 (fi) 2009-02-13 2024-02-27 Boehringer Ingelheim Int Glukopyranosylidifenylimetaanijohdannaisia sisältävä farmaseuttinen koostumus, niiden farmaseuttinen annostusmuoto, niiden valmistusmenetelmä ja niiden käyttö potilaan glukemiasäädön parantamiseksi
CN105343880A (zh) 2009-04-16 2016-02-24 大正制药株式会社 药物组合物
CN102574829B (zh) 2009-09-30 2015-07-01 贝林格尔.英格海姆国际有限公司 吡喃葡萄糖基取代的苄基-苯衍生物的制备方法
CN102549005B (zh) 2009-09-30 2015-08-26 贝林格尔.英格海姆国际有限公司 1-氯-4-(β-D-吡喃葡萄糖-1-基)-2-[4-((S)-四氢呋喃-3-基氧基)-苄基]-苯的晶型的制备方法
SG10201707020TA (en) * 2012-05-02 2017-10-30 Boehringer Ingelheim Int Substituted 3-haloallylamine inhibitors of ssao and uses thereof

Also Published As

Publication number Publication date
KR20190070956A (ko) 2019-06-21
WO2018073154A1 (en) 2018-04-26
CN109843279A (zh) 2019-06-04
CL2019000935A1 (es) 2019-08-09
AU2017344882A1 (en) 2019-03-28
EP3528800A1 (en) 2019-08-28
IL265989A (en) 2019-06-30
US20210212968A1 (en) 2021-07-15
EA201990951A1 (ru) 2019-11-29
BR112019005930A2 (pt) 2019-06-11
CA3041169A1 (en) 2018-04-26
PH12019500845A1 (en) 2019-12-02
JP2019531320A (ja) 2019-10-31

Similar Documents

Publication Publication Date Title
PH12019500845A1 (en) Combinations comprising an ssao/vap-1 inhibitor and a sglt2 inhibitor, uses thereof
MX2018003331A (es) Administracion de potenciadores de regulador de la conductancia transmembrana de fibrosis quistica (cftr) deuterados.
MX2021013830A (es) Inhibidores de ezh2 para tratar linfomas.
MX2020012595A (es) Composiciones farmaceuticas topicas.
MX2020008258A (es) Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos.
MX2018001659A (es) Terapia de combinacion que usa irinotecan liposomal y un inhibidor de poli(adp-ribosa) polimerasa (parp) para el tratamiento del cancer.
MX2024010140A (es) Nuevos metodos.
WO2016133903A3 (en) Combination therapy for cancer treatment
MX2017017138A (es) Conjugados homogeneos especificos de sitio con inhibidores de ksp.
CA2908742C (en) Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer
PH12016502352A1 (en) Pharmaceutical composition
MX2021002322A (es) Nuevos metodos.
TW201613578A (en) Pharmaceutical combinations
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
WO2018208793A8 (en) S-NITROSOGLUTATHIOME INHIBITORS (GSNO) AND GSNO REDUCTASE USEFUL IN THERAPY
MX2020001727A (es) Terapia de combinacion.
MX2019013862A (es) Terapia de combinacion.
CA2902116C (en) Pyrrolopyridine derivatives and their use as inhibitors of ssao activity
WO2016029136A8 (en) 3-amidobenzamides and uses thereof for increasing cellular levels of a3g
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
MX2024005453A (es) Composiciones y tratamientos con nirogacestat.
WO2015035410A8 (en) Cancer therapy
WO2019043176A3 (en) HISTONE-DEACETYLASE INHIBITOR IN COMBINATION WITH ANTIMETABOLITE AGENT FOR CANCER THERAPY
MX2022014792A (es) Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican.
MX2019002901A (es) Tratamiento de esclerosis multiple con chs-131.